Form 4: Abbott EVP Moreland Reports Share Dispositions

Abbott Laboratories Executive Vice President Mary K. Moreland reported the disposition of 5,243 common shares through a tax-related transaction and a sale.

Summary

• Mary K. Moreland, Executive Vice President of Abbott Laboratories (ABT), reported changes in her beneficial ownership.
• On February 27, 2026, 4,630 common shares were disposed of at a price of $116.26 per share, identified as a transaction for tax withholding purposes (Transaction Code F).
• On March 2, 2026, an additional 613 common shares were sold at a price of $115.58 per share (Transaction Code S).
• Following these transactions, Moreland directly holds 104,291 common shares.
• Additionally, 11,845 common shares are held indirectly in the Abbott Laboratories Stock Retirement Trust as of February 27, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The tax-related disposition is routine, and the open market sale is relatively small, not indicating a strong positive or negative signal for the company's prospects.

Negatives

• Insider sales, even if routine or for personal reasons, can sometimes be perceived negatively by the market, though the volume in this filing is relatively small compared to total holdings.

Industry Context

StockSavvy.ai notes that insider transactions, particularly routine tax-related dispositions (F-code) and smaller sales (S-code), are common occurrences across all industries and typically do not signal significant shifts in company strategy or performance unless they involve very large volumes or multiple executives.

Comparison to Industry Standards

• Insider sales of this magnitude by an executive are generally within the normal range for personal financial planning or tax obligations in large-cap pharmaceutical and medical device companies like Johnson & Johnson or Medtronic.
• These transactions do not indicate a deviation from typical executive stock management practices within the industry.

Stakeholder Impact

• Minimal direct impact on shareholders, employees, customers, suppliers, or creditors, as these are routine personal financial transactions by an executive.

Key Dates

Recommendation

The reported insider transactions are routine, including a tax-related disposition and a relatively small open market sale. These transactions do not provide sufficient new information to warrant a change in investment thesis for Abbott Laboratories, thus a 'hold' recommendation is appropriate.

Keywords

Abbott Laboratories, ABT, Insider Trading, Form 4, Share Sale, Executive Compensation, Mary K. Moreland, Stock Disposition